EP2362911A4 - Expressionsvektor und verfahren damit - Google Patents

Expressionsvektor und verfahren damit

Info

Publication number
EP2362911A4
EP2362911A4 EP09823138A EP09823138A EP2362911A4 EP 2362911 A4 EP2362911 A4 EP 2362911A4 EP 09823138 A EP09823138 A EP 09823138A EP 09823138 A EP09823138 A EP 09823138A EP 2362911 A4 EP2362911 A4 EP 2362911A4
Authority
EP
European Patent Office
Prior art keywords
processes
expression vector
vector
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09823138A
Other languages
English (en)
French (fr)
Other versions
EP2362911A1 (de
Inventor
Villoo Morawala Patell
Sunil Shekar
Srinivas Ireni
Gopal Dyaga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avesthagen Ltd
Original Assignee
Avesthagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avesthagen Ltd filed Critical Avesthagen Ltd
Publication of EP2362911A1 publication Critical patent/EP2362911A1/de
Publication of EP2362911A4 publication Critical patent/EP2362911A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
EP09823138A 2008-10-28 2009-10-23 Expressionsvektor und verfahren damit Withdrawn EP2362911A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2614CH2008 2008-10-28
PCT/IB2009/007207 WO2010049777A1 (en) 2008-10-28 2009-10-23 An expression vector and processes thereof

Publications (2)

Publication Number Publication Date
EP2362911A1 EP2362911A1 (de) 2011-09-07
EP2362911A4 true EP2362911A4 (de) 2012-07-18

Family

ID=42128314

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09823138A Withdrawn EP2362911A4 (de) 2008-10-28 2009-10-23 Expressionsvektor und verfahren damit

Country Status (7)

Country Link
EP (1) EP2362911A4 (de)
CN (1) CN102257141A (de)
AP (1) AP2011005739A0 (de)
AU (1) AU2009309387A1 (de)
BR (1) BRPI0914484A2 (de)
WO (1) WO2010049777A1 (de)
ZA (1) ZA201103960B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011015916A2 (en) * 2009-08-03 2011-02-10 Avesthagen Limited Vectors and compounds for expression of recombinant infliximab
WO2011015917A2 (en) * 2009-08-03 2011-02-10 Avesthagen Limited Vectors and compounds for expression of recombinant tnk-tpa (tenecteplase)
WO2011015924A2 (en) * 2009-08-03 2011-02-10 Avesthagen Limited Vectors and compounds for expression of recombinant trastuzumab
WO2011015918A2 (en) * 2009-08-03 2011-02-10 Avesthagen Limited Vectors and compounds for expression of recombinant cetuximab
JP6018195B2 (ja) * 2011-07-08 2016-11-02 シルバイオテック エス．アー． 哺乳動物静止細胞を可逆的に不死化する遺伝子導入系
WO2014120975A1 (en) * 2013-02-01 2014-08-07 California Institute Of Technology Antibody-mediated immunocontraception
US10966414B2 (en) 2015-05-26 2021-04-06 California Institute Of Technology Population control using engineered translocations
US12157883B2 (en) 2017-05-05 2024-12-03 California Institute Of Technology DNA sequence modification-based gene drive
US11965172B2 (en) 2018-11-05 2024-04-23 California Institute Of Technology DNA sequence modification-based gene drive

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074969A2 (en) * 2001-01-26 2002-09-26 University Of Lausanne Matrix attachment regions and methods for use thereof
WO2008023247A2 (en) * 2006-08-23 2008-02-28 Selexis S.A. Matrix attachment regions (mars) for increasing transcription and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US7541512B2 (en) * 2001-03-30 2009-06-02 Synageva Biopharma Corp. Avians containing a lysozyme promoter transgene
WO2005047512A2 (en) * 2003-11-12 2005-05-26 Shering Corporation Plasmid system for multigene expression
CN102177240A (zh) * 2008-08-12 2011-09-07 阿维斯塔根有限公司 表达载体及其方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074969A2 (en) * 2001-01-26 2002-09-26 University Of Lausanne Matrix attachment regions and methods for use thereof
WO2008023247A2 (en) * 2006-08-23 2008-02-28 Selexis S.A. Matrix attachment regions (mars) for increasing transcription and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BENHAM C ET AL: "Stress-induced duplex DNA destabilization in scaffold/matrix attachment regions", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 274, no. 2, 28 November 1997 (1997-11-28), pages 181 - 196, XP004453808, ISSN: 0022-2836, DOI: 10.1006/JMBI.1997.1385 *
LIEBICH INES ET AL: "S/MARt DB: A database on scaffold/matrix attached regions", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 30, no. 1, 1 January 2002 (2002-01-01), pages 372 - 374, XP002465967, ISSN: 0305-1048, DOI: 10.1093/NAR/30.1.372 *
See also references of WO2010049777A1 *
VON KRIES J P ET AL: "A matrix/scaffold attachment region binding protein: Identification, purification, and mode of binding", CELL, CELL PRESS, US, vol. 64, no. 1, 11 January 1991 (1991-01-11), pages 123 - 135, XP024244953, ISSN: 0092-8674, [retrieved on 19910111], DOI: 10.1016/0092-8674(91)90214-J *
WEITZEL ET AL: "Chicken MAR-binding protein ARBP is homologous to rat methyl-CpG-binding protein MeCP2.", MOLECULAR AND CELLULAR BIOLOGY, vol. 17, no. 9, 1 September 1997 (1997-09-01), pages 5656 - 5666, XP055028913, ISSN: 0270-7306 *

Also Published As

Publication number Publication date
AP2011005739A0 (en) 2011-06-30
BRPI0914484A2 (pt) 2015-09-01
AU2009309387A1 (en) 2010-05-06
ZA201103960B (en) 2012-03-28
CN102257141A (zh) 2011-11-23
EP2362911A1 (de) 2011-09-07
WO2010049777A1 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
IL210804A (en) Benzylidenehydrazides and their uses
PL3222615T3 (pl) Środki wiążące psma i ich zastosowania
ZA201101896B (en) Frizzled-binding agents and uses thereof
IL206774A0 (en) Improved mammalian expression vectors and uses thereof
IL219882A0 (en) System for increasing gene expression and vector comprising the system
GB0914644D0 (en) Novel agents and uses thereof
GB0810912D0 (en) Vector
PT2274422T (pt) Vetor de expressão
GB0808575D0 (en) Compilign and linking
ZA201103960B (en) An expression vector and processes thereof
EP2291377A4 (de) Imidazopyrimidinone und ihre verwendungen
ZA201101882B (en) An expression vector and a method thereof
GB0820631D0 (en) Vectors
ZA201103456B (en) Leukolectins and uses thereof
EP2247601A4 (de) Thiazopyrimidinone und anwendungen davon
SI2367943T1 (sl) Sesalski ekspresijski vektor
GB0912744D0 (en) Methods and uses
GB0810154D0 (en) Expression vector
GB0813359D0 (en) Halfin and/or platerfin
GB0808857D0 (en) Methdos and uses
GB0810609D0 (en) Methods and uses
GB0816523D0 (en) Methods and uses
TWI369138B (en) Speaker and application thereof
GB0816561D0 (en) Peptides and uses thereof
GB0910620D0 (en) Agents and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110530

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20120619

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101ALI20120613BHEP

Ipc: C12N 15/67 20060101AFI20120613BHEP

Ipc: C12N 15/13 20060101ALI20120613BHEP

Ipc: C12N 15/85 20060101ALI20120613BHEP

Ipc: C07K 16/00 20060101ALI20120613BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130530